Antabio is a biopharmaceutical company located in Labège (31) dedicated to the development of new treatments against antibiotic-resistant infections.

Antabio is currently working on three main research areas:
– MBLi program (Metallo-β-Lactamases inhibitors): development of inhibitors of metallo beta-lactamases, enzymes responsible for the emergence of multi-resistant to antibiotics, for the treatment of severe infections in hospitals;
– PEi program (Pseudomonas Elastase inhibitors): development of antibiotic adjuvants aimed at eradicating chronic Pseudomonas lung infections in cystic fibrosis patients;
– SBLi program (Serine beta-lactamases inhibitors): develops a new and powerful inhibitor to fight against nosocomial pneumonia.

The company employs about ten people and has surrounded itself with recognized experts in the sector. Antabio has also received the support of various leading international pharmaceutical organizations (CARB-X and Wellcome Trust).